Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 57

1.

An in vitro-in vivo model of epithelial mesenchymal transition in triple negative breast cancer.

Zhai Y, Santucci-Pereira J, de Cicco RL, Russo IH, Russo J.

Drug Discov Today Dis Mech. 2012 Summer;9(1-2):e35-e40.

2.

Epithelial to mesenchymal transition markers expressed in circulating tumour cells of early and metastatic breast cancer patients.

Kallergi G, Papadaki MA, Politaki E, Mavroudis D, Georgoulias V, Agelaki S.

Breast Cancer Res. 2011 Jun 10;13(3):R59. doi: 10.1186/bcr2896.

3.

CD146, an epithelial-mesenchymal transition inducer, is associated with triple-negative breast cancer.

Zeng Q, Li W, Lu D, Wu Z, Duan H, Luo Y, Feng J, Yang D, Fu L, Yan X.

Proc Natl Acad Sci U S A. 2012 Jan 24;109(4):1127-32. doi: 10.1073/pnas.1111053108. Epub 2011 Dec 30.

4.

Metadherin enhances the invasiveness of breast cancer cells by inducing epithelial to mesenchymal transition.

Li X, Kong X, Huo Q, Guo H, Yan S, Yuan C, Moran MS, Shao C, Yang Q.

Cancer Sci. 2011 Jun;102(6):1151-7. doi: 10.1111/j.1349-7006.2011.01919.x. Epub 2011 Apr 5.

5.

Two possible mechanisms of epithelial to mesenchymal transition in invasive ductal breast cancer.

Dubois-Marshall S, Thomas JS, Faratian D, Harrison DJ, Katz E.

Clin Exp Metastasis. 2011 Dec;28(8):811-8. doi: 10.1007/s10585-011-9412-x. Epub 2011 Jul 26.

PMID:
21789718
6.

A dynamic in vivo model of epithelial-to-mesenchymal transitions in circulating tumor cells and metastases of breast cancer.

Bonnomet A, Syne L, Brysse A, Feyereisen E, Thompson EW, Noël A, Foidart JM, Birembaut P, Polette M, Gilles C.

Oncogene. 2012 Aug 16;31(33):3741-53. doi: 10.1038/onc.2011.540. Epub 2011 Nov 28.

PMID:
22120722
7.

EMT transcription factors snail and slug directly contribute to cisplatin resistance in ovarian cancer.

Haslehurst AM, Koti M, Dharsee M, Nuin P, Evans K, Geraci J, Childs T, Chen J, Li J, Weberpals J, Davey S, Squire J, Park PC, Feilotter H.

BMC Cancer. 2012 Mar 19;12:91. doi: 10.1186/1471-2407-12-91.

8.

SOX4 induces epithelial-mesenchymal transition and contributes to breast cancer progression.

Zhang J, Liang Q, Lei Y, Yao M, Li L, Gao X, Feng J, Zhang Y, Gao H, Liu DX, Lu J, Huang B.

Cancer Res. 2012 Sep 1;72(17):4597-608. doi: 10.1158/0008-5472.CAN-12-1045. Epub 2012 Jul 11.

9.

Resveratrol inhibits TGF-β1-induced epithelial-to-mesenchymal transition and suppresses lung cancer invasion and metastasis.

Wang H, Zhang H, Tang L, Chen H, Wu C, Zhao M, Yang Y, Chen X, Liu G.

Toxicology. 2013 Jan 7;303:139-46. doi: 10.1016/j.tox.2012.09.017. Epub 2012 Nov 9.

PMID:
23146760
10.

Fucoidan induces changes in the epithelial to mesenchymal transition and decreases metastasis by enhancing ubiquitin-dependent TGFβ receptor degradation in breast cancer.

Hsu HY, Lin TY, Hwang PA, Tseng LM, Chen RH, Tsao SM, Hsu J.

Carcinogenesis. 2013 Apr;34(4):874-84. doi: 10.1093/carcin/bgs396. Epub 2012 Dec 28.

11.

Vimentin regulates EMT induction by Slug and oncogenic H-Ras and migration by governing Axl expression in breast cancer.

Vuoriluoto K, Haugen H, Kiviluoto S, Mpindi JP, Nevo J, Gjerdrum C, Tiron C, Lorens JB, Ivaska J.

Oncogene. 2011 Mar 24;30(12):1436-48. doi: 10.1038/onc.2010.509. Epub 2010 Nov 8.

PMID:
21057535
12.

HAb18G/CD147 promotes epithelial-mesenchymal transition through TGF-β signaling and is transcriptionally regulated by Slug.

Wu J, Ru NY, Zhang Y, Li Y, Wei D, Ren Z, Huang XF, Chen ZN, Bian H.

Oncogene. 2011 Oct 27;30(43):4410-27. doi: 10.1038/onc.2011.149. Epub 2011 May 2.

PMID:
21532623
13.

Potential role of mesenchymal stem cells (MSCs) in the breast tumour microenvironment: stimulation of epithelial to mesenchymal transition (EMT).

Martin FT, Dwyer RM, Kelly J, Khan S, Murphy JM, Curran C, Miller N, Hennessy E, Dockery P, Barry FP, O'Brien T, Kerin MJ.

Breast Cancer Res Treat. 2010 Nov;124(2):317-26. doi: 10.1007/s10549-010-0734-1. Epub 2010 Jan 20.

PMID:
20087650
14.

Epithelial-mesenchymal transition in breast cancer correlates with high histological grade and triple-negative phenotype.

Jeong H, Ryu YJ, An J, Lee Y, Kim A.

Histopathology. 2012 May;60(6B):E87-95. doi: 10.1111/j.1365-2559.2012.04195.x. Epub 2012 Mar 22.

PMID:
22439911
15.

CD146 expression is associated with a poor prognosis in human breast tumors and with enhanced motility in breast cancer cell lines.

Zabouo G, Imbert AM, Jacquemier J, Finetti P, Moreau T, Esterni B, Birnbaum D, Bertucci F, Chabannon C.

Breast Cancer Res. 2009;11(1):R1. doi: 10.1186/bcr2215. Epub 2009 Jan 5.

16.

Epithelial-mesenchymal transition in breast cancer relates to the basal-like phenotype.

Sarrió D, Rodriguez-Pinilla SM, Hardisson D, Cano A, Moreno-Bueno G, Palacios J.

Cancer Res. 2008 Feb 15;68(4):989-97. doi: 10.1158/0008-5472.CAN-07-2017.

17.

Mesenchymal stem cells play a potential role in regulating the establishment and maintenance of epithelial-mesenchymal transition in MCF7 human breast cancer cells by paracrine and induced autocrine TGF-β.

Xu Q, Wang L, Li H, Han Q, Li J, Qu X, Huang S, Zhao RC.

Int J Oncol. 2012 Sep;41(3):959-68. doi: 10.3892/ijo.2012.1541. Epub 2012 Jul 3.

PMID:
22766682
18.

Metformin against TGFβ-induced epithelial-to-mesenchymal transition (EMT): from cancer stem cells to aging-associated fibrosis.

Cufí S, Vazquez-Martin A, Oliveras-Ferraros C, Martin-Castillo B, Joven J, Menendez JA.

Cell Cycle. 2010 Nov 15;9(22):4461-8. Epub 2010 Nov 15.

PMID:
21088486
19.

Phthalates stimulate the epithelial to mesenchymal transition through an HDAC6-dependent mechanism in human breast epithelial stem cells.

Hsieh TH, Tsai CF, Hsu CY, Kuo PL, Lee JN, Chai CY, Hou MF, Chang CC, Long CY, Ko YC, Tsai EM.

Toxicol Sci. 2012 Aug;128(2):365-76. doi: 10.1093/toxsci/kfs163. Epub 2012 May 2.

20.

Identification of a GαGβγ, AKT and PKCα signalome associated with invasive growth in two genetic models of human breast cancer cell epithelial-to-mesenchymal transition.

Ouelaa-Benslama R, De Wever O, Hendrix A, Sabbah M, Lambein K, Land D, Prévost G, Bracke M, Hung MC, Larsen AK, Emami S, Gespach C.

Int J Oncol. 2012 Jul;41(1):189-200. doi: 10.3892/ijo.2012.1457. Epub 2012 Apr 30.

PMID:
22552300
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk